Acute Granulocytic Leukemia

Acute granulocytic leukemia is a fast-growing blood cancer. It starts in the bone marrow, the soft tissue inside bones that makes new blood cells. In this disease, immature myeloid cells (called myeloblasts) grow out of control. They crowd out normal cells that should become healthy red cells, white cells, and platelets. Because of this, the body cannot carry oxygen well, cannot fight infections well, and cannot stop bleeding easily. Doctors diagnose AML by blood tests and bone-marrow tests. Modern care also studies the leukemia’s genes because genes help guide treatment and predict outcome. NCBICancer.gov

Acute granulocytic leukemia (AGL) is another name for acute myelogenous/myeloid leukemia (AML)—a fast-growing blood and bone-marrow cancer that starts in early “myeloid” cells (the cells that normally become neutrophils, eosinophils, basophils, monocytes, and red cells/platelets). In AML, these immature cells (called myeloblasts) stop maturing, multiply quickly, crowd out healthy cells, and spill into the blood. Because of that, people develop anemia (low red cells → tiredness, short breath), neutropenia (low infection-fighting cells → fever/infections), and thrombocytopenia (low platelets → easy bruising/bleeding). AML is an emergency cancer that needs treatment right away; there isn’t a numbered “stage” system like many solid tumors—doctors classify it by cell genetics (mutations), patient fitness, and response to therapy. You may also see AML called acute myeloblastic leukemia, acute non-lymphocytic leukemia, or acute granulocytic leukemia—these all refer to the same overall disease category. Mayo ClinicNCBI

Another names

Acute granulocytic leukemia has several names used in textbooks and older articles. The modern, preferred name is acute myeloid leukemia (AML). You may also see acute myelogenous leukemia and acute non-lymphocytic leukemia (ANLL)—both mean the same broad disease group. Within AML, a special subtype is acute promyelocytic leukemia (APL), caused by the PML-RARA fusion gene. In older naming systems, some types were called myeloblastic or myelomonocytic leukemia; these map to today’s genetic or lineage-based AML groups. Knowing the synonyms helps when reading older studies and also when comparing different classification systems. PMC+1

Types

Doctors classify AML in two main ways: by modern genetic/clinical categories and by the older FAB (French-American-British) M0–M7 system. Both are still used for teaching and for matching clinical features.

A. Modern genetic/clinical categories (WHO 2022 / ICC overview).
These categories use specific chromosome changes and gene mutations, or clinical settings such as therapy-related disease. Key groups include:

• AML with defining genetic abnormalities, such as:

  • RUNX1–RUNX1T1 (t(8;21))—often shows large blasts with Auer rods and maturing neutrophils.

  • CBFB–MYH11 (inv(16)/t(16;16))—often with eosinophils in marrow.

  • PML–RARA (t(15;17))—this is APL, which presents with bleeding due to DIC but is highly curable when treated promptly.

  • NPM1-mutated AML—common in adults; prognosis depends on co-mutations like FLT3-ITD.

  • CEBPA (bZIP)-mutated AML—often favorable risk when biallelic.

  • KMT2A (MLL)-rearranged, MECOM (EVI1)-rearranged, NUP98-rearranged, and other less common fusions.

• AML, myelodysplasia-related (AML-MR)—arises from prior MDS or with specific MDS-related mutations/changes.

• Therapy-related myeloid neoplasms (t-MN)—develop after prior chemotherapy or radiation.
  These genetic labels matter because treatments and outcomes differ by mutation or fusion. PMCNature

B. Older FAB categories (still useful language).

• M0: Minimally differentiated AML.

• M1: Without maturation.

• M2: With maturation.

• M3: Acute promyelocytic leukemia (APL).

• M4: Myelomonocytic; M4Eo variant with eosinophils.

• M5: Monocytic.

• M6: Erythroid.

• M7: Megakaryoblastic.
  Clinicians still reference FAB terms because they describe how cells look and behave under the microscope, but genetics now lead the decision-making. PMC

Causes

In most people, the exact single “cause” is not known. AML usually comes from a mix of age-related genetic changes, exposures, or inherited risks. These are well-described risk factors.

1. Older age. AML is more common as we get older. Age brings more random DNA changes in stem cells. Cancer.govMayo Clinic

2. Male sex. Men have a slightly higher risk than women for reasons not fully known. Cancer.gov

3. Cigarette smoking. Toxins reach the marrow through the blood and damage DNA, raising AML risk. American Cancer Society

4. Benzene exposure. Long-term exposure (certain industries or solvents) can injure marrow DNA. Cancer.gov

5. High-dose radiation exposure. Survivors of nuclear accidents or high radiation doses have higher risk. Mayo Clinic

6. Prior chemotherapy (alkylators, topoisomerase II inhibitors). These life-saving drugs can, rarely, lead to therapy-related AML years later. Cancer.gov

7. Prior external-beam radiation for cancer. Radiation can add to later AML risk, especially with certain drugs. Cancer.gov

8. Myelodysplastic syndrome (MDS). MDS can evolve into AML when blasts increase. Cancer.gov

9. Myeloproliferative neoplasms (MPN). Some MPNs can transform into AML over time. (Clinical consensus summarized in guidelines.) ASH Publications

10. Clonal hematopoiesis (CHIP). Age-related “pre-leukemia” clones with mutations like DNMT3A, TET2, ASXL1 increase later AML risk. PMC

11. Inherited RUNX1 mutation (familial platelet disorder). This raises lifetime AML risk. ASH Publications

12. Inherited CEBPA mutation (familial AML). Families with germline CEBPA can develop AML at young ages. ASH Publications

13. GATA2 deficiency. An inherited marrow failure/immune syndrome that predisposes to AML/MDS. ASH Publications

14. Down syndrome (Trisomy 21). Raises risk of acute leukemias, especially in childhood; adult risk is also recognized. Mayo Clinic

15. Fanconi anemia. An inherited DNA-repair disorder with strong risk for AML. ASH Publications

16. Neurofibromatosis type 1, Bloom syndrome, ataxia-telangiectasia. Rare inherited conditions linked to higher AML risk. ASH Publications

17. Aplastic anemia history. Some people with severe marrow failure later develop AML/MDS. (Guideline/consensus.) ASH Publications

18. Obesity. Some studies show higher leukemia risk with obesity due to chronic inflammation and hormonal effects. (Epidemiology summaries.) Mayo Clinic

19. Environmental/occupational mixtures. Long exposure to certain industrial chemicals beyond benzene may add risk, though evidence varies. Cancer.gov

20. Family history of blood cancers. Even without a single known gene, clustering suggests shared genetic or environmental risks. (Guideline summaries.) ASH Publications

Symptoms

1. Tiredness and weakness. Low red cells (anemia) reduce oxygen delivery; you feel drained and short of breath. American Cancer Society

2. Pale skin. Anemia makes the skin and inside of lower eyelids look pale. American Cancer Society

3. Infections that keep coming back. Low normal white cells, especially neutrophils, cause frequent or severe infections. Fever is common. American Cancer Society

4. Fever. May come from infection or from the leukemia itself. American Cancer Society

5. Easy bruising and bleeding. Low platelets lead to nosebleeds, gum bleeding, or heavy periods. American Cancer Society

6. Tiny red or purple spots (petechiae). These are small skin bleeds from low platelets. American Cancer Society

7. Bone or joint pain. Crowded marrow raises pressure and causes aching. American Cancer Society

8. Fullness in the belly (enlarged spleen or liver). The organs can enlarge when they filter leukemia cells. American Cancer Society

9. Weight loss and poor appetite. Cancer uses energy and may reduce appetite. American Cancer Society

10. Night sweats. Common with active blood cancers. American Cancer Society

11. Shortness of breath. From anemia or, rarely, from very high white counts (leukostasis) that thicken the blood. American Cancer Society

12. Headache, dizziness, or vision changes. Can happen if white counts are extremely high or if anemia is severe. American Cancer Society

13. Gum swelling or bleeding. More common in monocytic forms of AML; gums look puffy and bleed easily. American Cancer Society

14. Skin lumps or rashes (leukemia cutis). Leukemia cells can collect in the skin. American Cancer Society

15. Bleeding problems with APL. The APL subtype can cause serious clotting and bleeding (DIC) early on. This is an emergency but very treatable when recognized quickly. PMC+1

Diagnostic tests

A) Physical examination (bedside observations)

1. Vital signs (temperature, pulse, blood pressure). Fever suggests infection; rapid pulse and low blood pressure may signal sepsis or bleeding risk. Exam guides how urgent care should be. American Cancer Society

2. Skin and mucosa check. Doctors look for pallor, bruises, petechiae, and gum swelling—visible clues of anemia, low platelets, or monocytic AML. American Cancer Society

3. Lymph node, spleen, and liver exam. Painless swelling of nodes, a big spleen, or a tender liver can occur in AML and related conditions. American Cancer Society

4. Neurologic screen. Headache, confusion, or vision changes can suggest leukostasis or bleeding; the exam helps decide on urgent tests. American Cancer Society

5. Cardiopulmonary exam. Listening to lungs and heart helps find infection, anemia-related strain, or fluid overload before treatment. American Cancer Society

B) “Manual tests” (hands-on or technician-performed methods)

6. Peripheral smear with manual differential. A lab professional reviews a stained blood slide under the microscope. They look for blasts, Auer rods, and abnormal neutrophils or monocytes. This often gives the first strong clue to AML. ASH Publications

7. Manual cytochemical stains (e.g., myeloperoxidase, Sudan Black B). These older—but still useful—stains help show myeloid lineage of blasts when flow cytometry is not immediately available. ASH Publications

8. Bone-marrow aspirate smear review. A hematopathologist manually examines marrow cells for percentage of blasts (≥20% blasts supports AML) and for maturation patterns. ASH Publications

9. Spleen percussion/palpation techniques. Bedside maneuvers can confirm mild splenic enlargement when imaging is not yet done; they support the overall picture with other findings. (Clinical exam practice.) ASH Publications

10. Fundoscopic (eye) exam. A handheld scope can show retinal hemorrhages or vessel changes in severe anemia/platelet loss or leukostasis. (Common bedside practice in hematology.) ASH Publications

C) Laboratory & pathological tests (core of diagnosis)

11. Complete blood count (CBC) with automated and manual differential. Often shows anemia, thrombocytopenia, and circulating blasts; white count can be high, normal, or low. ASH Publications

12. Bone-marrow aspiration and biopsy. This is the gold standard. It measures blast percentage, shows cell morphology, and provides material for all advanced tests below. ASH Publications

13. Flow cytometry immunophenotyping. Labels cells with antibodies to define myeloid markers (CD13, CD33, MPO, etc.) and to distinguish AML from ALL or other entities. ASH Publications

14. Conventional cytogenetics (karyotype). Looks for chromosome changes such as t(8;21), inv(16), and others that define type and risk group. PMC

15. FISH (fluorescence in situ hybridization) panels. Fast detection of key fusions (e.g., PML-RARA in APL) even when karyotype is unclear. Rapid APL detection saves lives. PMC

16. Molecular testing (PCR/NGS). Finds gene mutations (e.g., NPM1, FLT3-ITD/TKD, CEBPA, IDH1/2, RUNX1). These guide prognosis and targeted drugs. Cancer.gov

17. Coagulation panel and DIC screen. PT/INR, aPTT, fibrinogen, D-dimer. Especially urgent in suspected APL, where DIC is common at diagnosis. PMC+1

18. Chemistry panel including uric acid, creatinine, potassium, phosphate, calcium, and LDH. These show cell-breakdown and kidney risk and help prevent tumor lysis complications. ASH Publications

D) Electrodiagnostic tests (supportive, not for confirming AML)

19. Electrocardiogram (ECG). Checks heart rhythm and QT interval before and during therapy (for example, with anthracyclines or other QT-affecting drugs) and to assess electrolyte problems from tumor lysis. Cancer.gov

E) Imaging tests (to look for complications or baseline status)

20. Chest X-ray or chest CT and targeted imaging (e.g., abdominal ultrasound, brain CT/MRI if symptoms). Imaging helps find pneumonia, bleeding, organ enlargement, or rare leukostasis-related complications. It also provides baselines before intensive care. ASH Publications

Non-pharmacological treatments

These do not replace leukemia drugs. They support strength, safety, mood, and daily function during/after treatment. Always clear any program with your oncology team, especially during neutropenia or low platelets.

Physiotherapy

1. Energy-conserving aerobic walking (very light to light intensity).
   Purpose: keep heart-lung fitness and reduce cancer-related fatigue. Mechanism: small, repeated aerobic bouts improve mitochondrial efficiency and cardiorespiratory conditioning without overtaxing you. Benefits: better stamina, sleep, mood; fewer deconditioning aches. Start with 5–10 minutes 1–2×/day on “good” hours; pause immediately for fever, dizziness, bleeding, or shortness of breath.

2. Interval pacing (walk-rest-walk).
   Purpose: get activity while honoring low energy. Mechanism: alternates brief effort with recovery to prevent overexertion during anemia. Benefits: similar total steps with less fatigue “payback,” steadier daily activity.

3. Gentle resistance bands for major muscle groups (2–3 days/week on “OK” labs).
   Purpose: preserve muscle mass lost during chemo and bed rest. Mechanism: low-load resistance stimulates muscle protein synthesis. Benefits: stronger transfers, easier stair/bed mobility, reduced falls. Avoid if platelets are very low or if there’s bone pain—ask your team for platelet-safe thresholds.

4. Sit-to-stand practice and functional leg strengthening.
   Purpose: protect independence. Mechanism: task-specific training strengthens quads/hips and builds balance. Benefits: safer bathroom use, fewer caregiver lifts.

5. Balance drills (tandem stance, heel-toe line stands by a counter).
   Purpose: reduce fall risk from weakness or chemo-induced neuropathy. Mechanism: challenges proprioception and ankle strategies in a controlled setting. Benefits: safer walking, confidence.

6. Flexibility and gentle range-of-motion (shoulder, hip, ankle).
   Purpose: keep joints moving when you’re less active. Mechanism: maintains capsule and muscle length. Benefits: less stiffness, easier dressing/bathing.

7. Breathing exercises and incentive spirometry.
   Purpose: expand lungs after bed rest and prevent atelectasis. Mechanism: deep-breath holds recruit alveoli. Benefits: easier breathing, fewer post-chemo chest complications.

8. Posture training (scapular sets, thoracic opening).
   Purpose: reduce neck/upper-back strain from bed time. Mechanism: activates postural stabilizers and opens the chest. Benefits: less ache, better breathing mechanics.

9. Gait training with device (cane/rollator) when fatigued.
   Purpose: safe mobility on low-energy days. Mechanism: redistributes load and improves stability. Benefits: fewer falls, longer safe distances.

10. Peripheral neuropathy self-care + desensitization (if present).
    Purpose: decrease tingling/pain from certain drugs; protect feet. Mechanism: graded textures, protective footwear, daily skin checks. Benefits: fewer wounds, steadier gait.

11. Orthostatic hypotension counter-maneuvers.
    Purpose: prevent dizziness when standing. Mechanism: calf squeezes, slow transitions, hydration plan as allowed. Benefits: fewer near-falls.

12. Lymphatic-safe swelling control (elevation, gentle calf pumps).
    Purpose: manage fluid shifts. Mechanism: muscle-pump assists venous/lymph return. Benefits: less ankle swelling discomfort.

13. Safe core activation (abdominal bracing) for back comfort.
    Purpose: protect spine during weakness. Mechanism: engages deep stabilizers without straining. Benefits: easier transfers.

14. Fatigue diary with graded activity scheduling.
    Purpose: match exercise to best energy window. Mechanism: activity-rest titration reduces “boom-bust.” Benefits: steadier progress.

15. In-hospital mobility “minimums.”
    Purpose: prevent rapid deconditioning. Mechanism: sit up for meals, short corridor walks with staff when labs/symptoms permit. Benefits: shorter rehab time.

Mind-body (and how it can influence biology)

16. Mindfulness-based stress reduction (MBSR) or paced breathing (4-6/min).
    Purpose: calm anxiety and improve sleep. Mechanism: downshifts sympathetic tone and inflammation pathways; stress reduction may influence gene expression of immune/inflammatory signals in a modest way. Benefits: lower perceived pain, steadier mood, better coping.

17. Cognitive-behavioral coping skills (brief CBT).
    Purpose: manage fear before labs/appointments. Mechanism: reframes threat thoughts; builds routines for uncertainty. Benefits: less distress, improved adherence.

18. Guided imagery for procedures.
    Purpose: reduce pain/needle anxiety. Mechanism: brain imagery dampens pain pathways. Benefits: easier blood draws/biopsies.

19. Sleep hygiene micro-plan.
    Purpose: restore healing sleep. Mechanism: light control, consistent wake time, stimulus control. Benefits: energy, mood, immune function support.

20. Music or art therapy.
    Purpose: emotional processing. Mechanism: engages reward/soothing networks. Benefits: less anxiety, more meaning.

Education & self-management

21. Infection-prevention coaching (food safety > strict “neutropenic diet”).
    Purpose: lower infection risk without harming nutrition. Mechanism & benefits: follow FDA-style food safety and hand hygiene; strict “neutropenic diets” haven’t shown lower infection or death in trials—safe food handling works and preserves quality of life. PMC+1Cancer Today

22. Central line (port/PICC) care training.
    Purpose: prevent line infections. Mechanism: sterile technique, daily checks, dressing care. Benefits: fewer ER visits.

23. Transfusion-safety and bleeding-risk teaching.
    Purpose: recognize bleeding signs early. Mechanism: platelet thresholds, stool/urine checks, nosebleed care. Benefits: timely help, fewer complications.

24. Medication adherence & interaction review.
    Purpose: take chemo/targeted pills correctly; avoid risky supplements. Mechanism: med calendar, pharmacist review. Benefits: better response, fewer interactions.

25. Return-to-daily-life plan (work/school/family roles).
    Purpose: rebuild routine gradually. Mechanism: graded goals with your care team/PT. Benefits: smoother recovery and independence.

Drug treatments

Doses and timing are individualized. The brief “typical use” below is not a prescription—always follow your oncologist’s plan.

1. Cytarabine (“Ara-C”) — Antimetabolite chemotherapy.
   Use: backbone of AML treatment (induction and consolidation). Typical timing: continuous IV infusion for 7 days during “7+3” induction; later, high-dose cycles for consolidation. Purpose: kill rapidly dividing myeloblasts. Mechanism: cytidine analog that blocks DNA synthesis. Side effects: low counts, mouth sores, fever/infections, at high doses—eye irritation (needs steroid eye drops) and rare neurotoxicity. PMCMedscape

2. Daunorubicin — Anthracycline chemotherapy.
   Use: paired with cytarabine in 7+3 induction. Mechanism: intercalates DNA; inhibits topoisomerase II. Benefits: proven remission rates; higher daunorubicin dose (e.g., 90 mg/m²) improved outcomes vs lower dose in trials. Side effects: low counts, nausea, hair loss, heart toxicity (lifetime dose tracking). eviq.org.au

3. Idarubicin — Anthracycline.
   Use: alternative to daunorubicin in 7+3. Mechanism/benefits/risks: similar to daunorubicin; heart function monitoring needed. Medscape

4. CPX-351 (daunorubicin + cytarabine in a liposomal 5:1 ratio; brand Vyxeos) — Liposomal chemo combination.
   Use: therapy-related AML or AML with myelodysplasia-related changes, especially in older adults; improved survival vs conventional 7+3 in that group. Mechanism: fixed synergistic molar ratio, targeted marrow uptake. Side effects: prolonged low counts, infections; careful supportive care is essential. ASH PublicationsWiley Online Library

5. Azacitidine (IV/subQ) or Oral azacitidine (CC-486) — Hypomethylating agents.
   Use: for patients not fit for intensive chemo; oral azacitidine is used as maintenance after remission to delay relapse. Mechanism: epigenetic reprogramming → blasts can mature/die. Side effects: low counts, GI upset. PMC

6. Decitabine — Hypomethylating agent.
   Use: alternative to azacitidine in unfit patients or specific schedules. Mechanism/risks: similar to azacitidine; cytopenias and infection risk require close monitoring.

7. Venetoclax — BCL-2 inhibitor (targeted).
   Use: combined with azacitidine or decitabine for newly diagnosed older/unfit AML; improves survival vs azacitidine alone. Mechanism: triggers cancer cell apoptosis. Side effects: low counts, tumor lysis risk early on; careful ramp-up and monitoring. New England Journal of Medicine

8. Midostaurin — FLT3 inhibitor (targeted).
   Use: add to 7+3 for newly diagnosed FLT3-mutated AML; improves overall survival in the CALGB/RATIFY trial. Mechanism: blocks mutant FLT3 signaling. Side effects: nausea, rash, QT prolongation—ECG monitoring as directed. New England Journal of MedicinePMC

9. Gilteritinib — FLT3 inhibitor (targeted).
   Use: relapsed/refractory FLT3-mutated AML; superior survival vs chemotherapy alone. Mechanism: selective FLT3 blockade. Side effects: liver enzyme rise, differentiation syndrome (rare), QT changes. New England Journal of MedicinePubMed

10. Quizartinib — FLT3-ITD inhibitor (targeted).
    Use: in some regions for FLT3-ITD AML per local approvals/protocols; discuss availability with your center. Mechanism/risks: similar FLT3 blockade; monitor QT interval (center-specific guidance).

11. Ivosidenib — IDH1 inhibitor (targeted).
    Use: adults with IDH1-mutated AML; as single agent in older/unfit newly diagnosed patients, and in combinations by protocol. Mechanism: blocks mutant IDH1 → lowers the oncometabolite 2-HG → allows maturation. Side effects: differentiation syndrome (fever, low BP, fluid in lungs—medical emergency), QT prolongation, liver test changes. U.S. Food and Drug AdministrationOncLive

12. Enasidenib — IDH2 inhibitor (targeted).
    Use: relapsed/refractory AML with IDH2 mutation. Mechanism/benefits: lowers 2-HG and promotes differentiation; watch carefully for differentiation syndrome. U.S. Food and Drug Administration

13. Gemtuzumab ozogamicin — Anti-CD33 antibody-drug conjugate.
    Use: selected newly diagnosed or relapsed CD33-positive AML cases, often combined with chemo in specified regimens; survival benefit in some groups. Mechanism: antibody delivers calicheamicin to CD33+ blasts. Side effects: liver veno-occlusive disease risk, low counts, infections.

14. Glasdegib + low-dose cytarabine (LDAC) — Hedgehog pathway inhibitor + chemo.
    Use: option for patients unfit for intensive therapy. Mechanism: inhibits SMO to target leukemia stem cell pathways; LDAC provides cytotoxic effect. Side effects: anemia, fatigue, taste changes, QT monitoring.

15. Hydroxyurea (short-term cytoreduction) — Antimetabolite.
    Use: quickly reduces very high white cell counts while definitive AML therapy is readied, especially in hyperleukocytosis or leukostasis risk. Mechanism: halts DNA synthesis in blasts. Side effects: typically transient; counts fall. Cytoreduction should not delay AML-directed therapy. ASH Publications

Dietary molecular supports

Evidence in AML is limited; the safest approach is adequate calories/protein, food-safety hygiene, and correction of true deficiencies. Strict “neutropenic diets” do not reduce infections versus safe-food-handling programs. PMC+1

1. Vitamin D (correct proven deficiency).
   Dose: per lab-guided plan (commonly 800–2000 IU/day maintenance; higher short-term repletion only if prescribed). Function/mechanism: supports bone/muscle and immune signaling; deficiency is common in chronic illness. Note: avoid mega-doses; check levels.

2. High-protein nutrition (whey or plant protein shakes).
   Dose: dietitian-guided to meet daily protein targets (often 1.0–1.5 g/kg/day if kidneys allow). Mechanism: supplies amino acids to maintain muscle and heal mucosa. Note: use pasteurized/prepared safely.

3. Omega-3 fatty acids (EPA/DHA) for appetite/inflammation.
   Dose: typical 1–2 g/day combined EPA/DHA with food if your team agrees. Mechanism: anti-inflammatory lipid mediators may help weight maintenance. Caution: bleeding risk if platelets very low—ask your doctor.

4. Soluble fiber/prebiotic foods (oats, bananas, cooked pulses).
   Function: feeds beneficial gut bacteria and supports regularity. Mechanism: short-chain fatty acid production. Caution: use cooked/peeled forms and excellent food hygiene during neutropenia.

5. Ginger (anti-nausea adjunct).
   Dose: dietary ginger or standardized capsules per clinician guidance. Mechanism: 5-HT3 and cholinergic effects. Note: may interact with anticoagulation—check first.

6. Glutamine (for mucositis support—mixed evidence).
   Dose: only if recommended by your team. Mechanism: fuel for enterocytes. Caution: not for everyone; discuss potential risks/benefits.

7. Thiamine and B-complex (replace deficits from poor intake).
   Mechanism: supports energy metabolism; low levels worsen fatigue.

8. Zinc (deficiency-only replacement).
   Mechanism: enzyme and barrier function support. Caution: too much zinc can lower copper; lab-guided only.

9. Electrolyte solutions (oral rehydration).
   Function: prevent dehydration during fevers/diarrhea. Mechanism: glucose-sodium cotransport improves absorption.

10. Food-safety protocol as a “nutritional intervention.”
    Mechanism: instead of blanket prohibitions, use handwashing, clean cutting boards, pasteurized dairy, thoroughly cooked meats/eggs, washed/peeled produce, and safe storage—this protects you without unnecessary nutrition limits. PMC+1

Immunity/regenerative/stem-cell–related” drugs

1. Filgrastim (G-CSF).
   Dose: as ordered (often daily injections during recovery). Function/mechanism: stimulates neutrophil production after chemo. Note: not for routine use during induction unless your team indicates; used to shorten neutropenia.

2. Sargramostim (GM-CSF).
   Function: stimulates broader myeloid recovery. Mechanism: GM-CSF receptor stimulation. Use: selected settings per protocol.

3. Epoetin alfa / darbepoetin (ESAs).
   Function: red cell production support in symptomatic anemia not due to iron/B12/folate deficiency. Caution: used carefully in oncology; risks/benefits reviewed case-by-case.

4. Intravenous immunoglobulin (IVIG).
   Function: passive antibodies for patients with recurrent infections and very low immunoglobulins. Mechanism: replaces humoral immunity.

5. Plerixafor (CXCR4 antagonist) for stem cell mobilization.
   Function: helps move stem cells from marrow into blood for collection in transplant pathways. Use: transplant programs as indicated.

6. Inactivated vaccines (influenza, COVID-19 updates, pneumococcal) when timing is safe.
   Function: priming future immune protection; not live vaccines during immunosuppression. Timing: your team will choose safe windows.

Procedures/surgeries

1. Allogeneic hematopoietic stem cell transplantation (HSCT).
   What: donor stem cells replace your marrow after conditioning chemo ± radiation. Why: for high-risk disease or relapse to provide the best chance for long-term control/cure via graft-versus-leukemia effect.

2. Leukapheresis (selected cases).
   What: apheresis machine removes excess white cells from blood. Why: short-term relief of leukostasis symptoms when white counts are extremely high; does not replace urgent AML therapy, and routine use hasn’t shown clear survival benefit—your team weighs risks/benefits carefully. ASH PublicationsPMCTaylor & Francis Online

3. Central venous catheter/port placement.
   What: surgical insertion of a reliable IV access device. Why: safe delivery of chemo, blood products, antibiotics, and blood draws.

4. Lumbar puncture with intrathecal chemotherapy (selected subtypes/symptoms).
   What: spinal fluid sampling and, when indicated, direct chemo into CSF. Why: evaluate/treat CNS involvement risk.

5. Splenectomy (rare, highly selected).
   What: surgical removal of the spleen. Why: occasionally for painful massive spleen or persistent low counts from sequestration when other options fail.

Prevention strategies

1. Food-safety hygiene over strict “neutropenic diets.” Wash hands/produce, eat pasteurized dairy, cook meats/eggs well, avoid raw seafood and unpasteurized juices. Evidence shows strict neutropenic diets don’t reduce infections vs safe-handling programs. PMC+1

2. Hand hygiene + mask in crowded/respiratory-illness seasons.

3. Central line care exactly as taught; daily site checks.

4. Prompt fever action plan (≥38.0 °C): go to hospital/ER immediately.

5. Vaccination plan (inactivated) scheduled by your team; vaccinate close contacts, too.

6. Avoid gardening/soil/aquariums/hot tubs during deep neutropenia.

7. Shave with electric razors; use soft toothbrush; stool softeners to avoid straining when platelets are low.

8. No NSAIDs without approval (bleeding/kidney risks); check all OTC/herbals.

9. Sun protection for chemo-sensitized skin; moisturize to protect barrier.

10. Keep a simple symptom & temperature diary to catch problems early.

When to see a doctor immediately

• Fever ≥38.0 °C (100.4 °F) once or persistent low-grade fever.

• New bleeding/bruising, tiny red dots (petechiae), or nose/gum bleeding that won’t stop.

• Shortness of breath, chest pain, severe headache, confusion, vision changes, or stroke-like symptoms (possible leukostasis emergency in the setting of very high counts). ACEP

• Severe mouth sores, inability to keep fluids down, diarrhea >6 times/day, or signs of dehydration.

• Line site redness, drainage, or pain.

• Sudden severe bone pain, swelling in one leg, or calf pain.

• Any new rash with fever or breathing symptoms (possible drug reaction or differentiation syndrome on targeted agents like IDH/FLT3 inhibitors). New England Journal of MedicineU.S. Food and Drug Administration

What to eat and what to avoid

Eat (prepared safely):

• Well-cooked proteins (eggs fully set; chicken/fish to safe temps), legumes, and pasteurized dairy/yogurt.

• Peeled or well-washed fruits; cooked vegetables; whole-grain breads and oats.

• Small, frequent meals with extra protein (shakes or soft foods on sore-mouth days).

• Plenty of fluids (oral rehydration solutions during diarrhea if your team agrees).

Avoid (especially during deep neutropenia):

• Raw or undercooked meat/seafood/eggs; unpasteurized milk/cheese/juice; salad bars and buffets.

• Herbal megadoses/high-dose antioxidant supplements during active chemo unless your oncologist explicitly okays them (possible interactions).

• Grapefruit/Seville orange if your targeted drug has a CYP3A interaction warning (ask your pharmacist).

• Alcohol beyond minimal amounts your team approves (can worsen cytopenias or interact with meds).

Note: Modern trials/meta-analyses show strict neutropenic diets don’t reduce infections versus standard food-safety practices—so focus on how food is handled, not needless restrictions. PMC+1

Frequently asked questions (FAQs)

1. Is “acute granulocytic leukemia” the same as AML?
   Yes. It’s one of the older names for acute myelogenous/myeloid leukemia; the terms are used interchangeably in many clinical sources. Mayo Clinic

2. What is the usual first treatment?
   Most fit adults receive induction chemotherapy with 7 days of cytarabine + 3 days of an anthracycline (daunorubicin or idarubicin), often with a targeted drug if a mutation is present. Medscape

3. What are “targeted” AML drugs?
   Medicines that block a mutation the leukemia uses to grow, like FLT3 (midostaurin/gilteritinib) or IDH1/2 (ivosidenib/enasidenib). They improve outcomes in the right patients. New England Journal of Medicine+1U.S. Food and Drug Administration+1

4. What if I’m not strong enough for intensive chemo?
   Options include azacitidine or decitabine, often combined with venetoclax, which improved survival compared with azacitidine alone. New England Journal of Medicine

5. What is CPX-351 and who gets it?
   It’s a liposomal combo of daunorubicin + cytarabine for therapy-related AML or AML with myelodysplasia-related changes, with survival benefits in older adults compared with 7+3. ASH Publications

6. Do I need a transplant?
   Some patients—especially with high-risk genetics or after relapse—benefit from allogeneic stem cell transplant for the best chance at long-term control. Your team decides using risk models and remission status.

7. Are “neutropenic diets” required?
   No. Studies and reviews show no reduction in infections or deaths versus good food-safety hygiene. Focus on safe handling and cooking. PMC+1

8. What is leukostasis and why is it dangerous?
   Very high blast counts make blood thick and can block flow to lungs/brain—an emergency needing immediate cytoreduction; leukapheresis may be used selectively but does not replace urgent chemo. ACEPASH Publications

9. Will exercise make me worse?
   When approved by your team and tailored to your labs/symptoms, gentle, graded activity helps fight fatigue and preserves function. Stop if you have fever, chest pain, bleeding, dizziness, or shortness of breath.

10. Can supplements cure AML?
    No. Supplements cannot treat leukemia. Some can interact with chemo/targeted drugs. Only correct proven deficiencies and always discuss any supplement first.

11. What is “differentiation syndrome”?
    A sudden inflammatory reaction where maturing leukemia cells release signals (seen with IDH or FLT3 inhibitors and in APL with ATRA). Symptoms include fever, low BP, breathing trouble—seek emergency care. New England Journal of MedicineU.S. Food and Drug Administration

12. How long will treatment take?
    Induction is weeks (often in hospital), consolidation cycles continue for months, and maintenance (e.g., oral azacitidine in selected cases) may follow. Timelines depend on your plan and marrow recovery. PMC

13. Why do I need so many transfusions?
    Chemo and AML both lower red cells and platelets; transfusions prevent dangerous anemia/bleeding while marrow recovers.

14. What raises infection risk most?
    Duration and depth of neutropenia, central lines, mucositis, and environmental exposures. That’s why prompt fever care and hygiene matter.

15. What symptoms should trigger urgent help at home?
    Fever ≥38.0 °C, bleeding you can’t stop, trouble breathing, confusion, chest pain, severe headache, new rash with fever, or severe weakness/dehydration. See the “When to see a doctor” list above. ACEP

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 07, 2025.

Previous

Types of Acute Myeloid Leukemia

Next

Acute Myeloblastic Leukemia (AML)

Related Articles

Added to wishlistRemoved from wishlist 0

Combined Immunodeficiency with Childhood-Onset Kaposi Sarcoma

Added to wishlistRemoved from wishlist 0

Collecting Duct Renal Cell Carcinoma

Added to wishlistRemoved from wishlist 0

Collecting Duct Carcinoma of the Kidney

Added to wishlistRemoved from wishlist 0

Kidney Collecting Duct Carcinoma